More recently, a Mendelian randomization study by Carter et al reported that genetic variants reducing the function of HMGCR (proxies for statin treatment) were associated with a reduced overall risk of cancer, whereas variants in other genes with influence on lipid metabolism (proxies for other lipid‐lowering therapies) were not.27 Here, HMGCR is linked to cancer.